vs

Side-by-side financial comparison of AerSale Corp (ASLE) and MEDIFAST INC (MED). Click either name above to swap in a different company.

AerSale Corp is the larger business by last-quarter revenue ($90.9M vs $75.1M, roughly 1.2× MEDIFAST INC). On growth, AerSale Corp posted the faster year-over-year revenue change (-4.0% vs -36.9%). AerSale Corp produced more free cash flow last quarter ($9.8M vs $-6.6M). Over the past eight quarters, AerSale Corp's revenue compounded faster (0.2% CAGR vs -34.4%).

AerSale, Inc. is a Doral, Florida-based global supplier of aftermarket commercial jet aircraft, engines, used materials, and aeronautical engineering services to passenger and cargo airlines, government, multinational original equipment manufacturers, and independent MROs. AerSale is a member of the Aircraft Fleet Recycling Association.

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

ASLE vs MED — Head-to-Head

Bigger by revenue
ASLE
ASLE
1.2× larger
ASLE
$90.9M
$75.1M
MED
Growing faster (revenue YoY)
ASLE
ASLE
+32.9% gap
ASLE
-4.0%
-36.9%
MED
More free cash flow
ASLE
ASLE
$16.4M more FCF
ASLE
$9.8M
$-6.6M
MED
Faster 2-yr revenue CAGR
ASLE
ASLE
Annualised
ASLE
0.2%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASLE
ASLE
MED
MED
Revenue
$90.9M
$75.1M
Net Profit
$5.4M
Gross Margin
34.1%
69.4%
Operating Margin
7.8%
-10.4%
Net Margin
5.9%
Revenue YoY
-4.0%
-36.9%
Net Profit YoY
99.7%
EPS (diluted)
$0.10
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASLE
ASLE
MED
MED
Q4 25
$90.9M
$75.1M
Q3 25
$71.2M
$89.4M
Q2 25
$107.4M
$105.6M
Q1 25
$65.8M
$115.7M
Q4 24
$94.7M
$119.0M
Q3 24
$82.7M
$140.2M
Q2 24
$77.1M
$168.6M
Q1 24
$90.5M
$174.7M
Net Profit
ASLE
ASLE
MED
MED
Q4 25
$5.4M
Q3 25
$-120.0K
$-2.3M
Q2 25
$8.6M
$2.5M
Q1 25
$-5.3M
$-772.0K
Q4 24
$2.7M
Q3 24
$509.0K
$1.1M
Q2 24
$-3.6M
$-8.2M
Q1 24
$6.3M
$8.3M
Gross Margin
ASLE
ASLE
MED
MED
Q4 25
34.1%
69.4%
Q3 25
30.2%
69.5%
Q2 25
32.9%
72.6%
Q1 25
27.3%
72.8%
Q4 24
31.4%
74.1%
Q3 24
28.6%
75.4%
Q2 24
28.2%
73.2%
Q1 24
31.8%
72.8%
Operating Margin
ASLE
ASLE
MED
MED
Q4 25
7.8%
-10.4%
Q3 25
4.0%
-4.6%
Q2 25
11.7%
-1.0%
Q1 25
-10.1%
-1.1%
Q4 24
5.2%
0.6%
Q3 24
2.4%
1.5%
Q2 24
-2.4%
-4.7%
Q1 24
5.2%
4.5%
Net Margin
ASLE
ASLE
MED
MED
Q4 25
5.9%
Q3 25
-0.2%
-2.5%
Q2 25
8.0%
2.3%
Q1 25
-8.0%
-0.7%
Q4 24
2.9%
Q3 24
0.6%
0.8%
Q2 24
-4.7%
-4.8%
Q1 24
6.9%
4.8%
EPS (diluted)
ASLE
ASLE
MED
MED
Q4 25
$0.10
$-1.64
Q3 25
$0.00
$-0.21
Q2 25
$0.18
$0.22
Q1 25
$-0.10
$-0.07
Q4 24
$0.05
$0.08
Q3 24
$0.01
$0.10
Q2 24
$-0.07
$-0.75
Q1 24
$0.12
$0.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASLE
ASLE
MED
MED
Cash + ST InvestmentsLiquidity on hand
$4.4M
$167.3M
Total DebtLower is stronger
$1.3M
Stockholders' EquityBook value
$424.4M
$198.9M
Total Assets
$640.5M
$248.0M
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASLE
ASLE
MED
MED
Q4 25
$4.4M
$167.3M
Q3 25
$5.3M
$173.5M
Q2 25
$5.7M
$162.7M
Q1 25
$4.7M
$164.6M
Q4 24
$4.7M
$162.3M
Q3 24
$9.8M
$170.0M
Q2 24
$4.3M
$163.5M
Q1 24
$2.6M
$156.4M
Total Debt
ASLE
ASLE
MED
MED
Q4 25
$1.3M
Q3 25
$1.5M
Q2 25
$907.0K
Q1 25
$1.1M
Q4 24
$1.2M
Q3 24
$376.0K
Q2 24
$522.0K
Q1 24
$3.5M
Stockholders' Equity
ASLE
ASLE
MED
MED
Q4 25
$424.4M
$198.9M
Q3 25
$417.1M
$214.7M
Q2 25
$415.9M
$216.0M
Q1 25
$406.5M
$211.0M
Q4 24
$455.6M
$210.1M
Q3 24
$451.5M
$207.3M
Q2 24
$449.8M
$205.3M
Q1 24
$452.0M
$211.0M
Total Assets
ASLE
ASLE
MED
MED
Q4 25
$640.5M
$248.0M
Q3 25
$646.3M
$268.2M
Q2 25
$646.7M
$269.3M
Q1 25
$646.1M
$280.0M
Q4 24
$604.7M
$284.2M
Q3 24
$601.5M
$291.2M
Q2 24
$598.7M
$293.5M
Q1 24
$571.7M
$302.8M
Debt / Equity
ASLE
ASLE
MED
MED
Q4 25
0.00×
Q3 25
0.00×
Q2 25
0.00×
Q1 25
0.00×
Q4 24
0.00×
Q3 24
0.00×
Q2 24
0.00×
Q1 24
0.01×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASLE
ASLE
MED
MED
Operating Cash FlowLast quarter
$11.4M
$-5.3M
Free Cash FlowOCF − Capex
$9.8M
$-6.6M
FCF MarginFCF / Revenue
10.8%
-8.8%
Capex IntensityCapex / Revenue
1.7%
1.8%
Cash ConversionOCF / Net Profit
2.11×
TTM Free Cash FlowTrailing 4 quarters
$-29.1M
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASLE
ASLE
MED
MED
Q4 25
$11.4M
$-5.3M
Q3 25
$-8.9M
$12.1M
Q2 25
$19.8M
$-3.4M
Q1 25
$-45.2M
$3.4M
Q4 24
$37.5M
$-4.9M
Q3 24
$10.4M
$9.1M
Q2 24
$-15.3M
$13.1M
Q1 24
$-21.5M
$7.3M
Free Cash Flow
ASLE
ASLE
MED
MED
Q4 25
$9.8M
$-6.6M
Q3 25
$-9.8M
$10.8M
Q2 25
$18.6M
$-4.8M
Q1 25
$-47.6M
$1.9M
Q4 24
$32.3M
$-7.2M
Q3 24
$8.9M
$7.7M
Q2 24
$-18.9M
$11.1M
Q1 24
$-25.0M
$5.4M
FCF Margin
ASLE
ASLE
MED
MED
Q4 25
10.8%
-8.8%
Q3 25
-13.8%
12.0%
Q2 25
17.3%
-4.5%
Q1 25
-72.4%
1.6%
Q4 24
34.0%
-6.1%
Q3 24
10.7%
5.5%
Q2 24
-24.6%
6.6%
Q1 24
-27.7%
3.1%
Capex Intensity
ASLE
ASLE
MED
MED
Q4 25
1.7%
1.8%
Q3 25
1.3%
1.5%
Q2 25
1.1%
1.3%
Q1 25
3.7%
1.3%
Q4 24
5.6%
1.9%
Q3 24
1.9%
1.0%
Q2 24
4.7%
1.1%
Q1 24
3.9%
1.1%
Cash Conversion
ASLE
ASLE
MED
MED
Q4 25
2.11×
Q3 25
Q2 25
2.31×
-1.36×
Q1 25
Q4 24
13.89×
Q3 24
20.52×
8.04×
Q2 24
Q1 24
-3.42×
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASLE
ASLE

Products$57.8M64%
Maintenance$23.2M26%
Leasing Arrangements$9.9M11%

MED
MED

Segment breakdown not available.

Related Comparisons